NOT MEDICAL ADVICE. No information on this site should be considered medical advice. Research peptides are not intended for human consumption — in-vitro lab use only. Consult a physician prior to introducing anything into the human body.
Peptide HubResearch Peptide Wiki
Support Us Join

Home/Weight Loss & Metabolic/Semaglutide

Semaglutide

An approved GLP-1 receptor agonist with a fatty-acid modification for once-weekly dosing in type 2 diabetes and chronic weight management.

Overview

Semaglutide is a synthetic analog of the incretin hormone glucagon-like peptide-1 (GLP-1), approved in multiple countries for type 2 diabetes and, at a higher dose, for chronic weight management. A fatty-acid side chain that binds albumin extends its half-life, supporting once-weekly subcutaneous (and once-daily oral) dosing. It is among the most extensively studied peptides in metabolic medicine.

Mechanism

Semaglutide is a potent and selective agonist of the GLP-1 receptor. Receptor activation enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite through central pathways, together producing glycemic control and weight loss.

Dosing

Approved use is by subcutaneous injection once weekly, with an oral formulation also available; doses are titrated over several weeks to limit gastrointestinal side effects. Research-peptide contexts mirror GLP-1 pharmacology but are not clinically validated.

  • Weekly subcutaneous injection is the approved injectable schedule
  • Gradual dose escalation over weeks is standard in approved regimens
  • The oral form requires specific administration conditions per its label

Expected Effects

  • Reductions in HbA1c in type 2 diabetes trials
  • Dose-dependent weight loss, forming the basis of the obesity indication
  • Reduced major adverse cardiovascular events reported in a cardiovascular outcomes trial in high-risk type 2 diabetes

Side Effects & Tolerability

Gastrointestinal effects such as nausea, vomiting, diarrhea, and constipation are common and dose-dependent. Labels include warnings for pancreatitis, gallbladder disease, hypoglycemia when combined with insulin or sulfonylureas, and thyroid C-cell tumors observed in rodents. Long-term clinical experience continues to accumulate.

Storage

Approved products are stored refrigerated before first use. For lyophilized research peptide, store cold and desiccated, protected from light, and follow the supplier certificate of analysis.

Related peptides

AdipotideInvestigational prohibitin-targeting pro-apoptotic peptide conjugate studied in obese mice and monkeys to reduce adipose vasculature; not tested in humans.Advanced Thermogenic Master AnalogsMarketing-style catalog label implying peptides that enhance thermogenesis; no defined compound exists under this name in the literature.AMPK & mTOR Balance AnalogsCatalog label implying peptides that modulate the AMPK/mTOR signaling balance; no specific compounds are characterized under this name.Amylin Analogs (Expanded)Class listing for synthetic analogs of the pancreatic hormone amylin; pramlintide is the approved reference agent, while novel long-acting analogs are investigational.Autophagy Enhancer Peptide AnalogsCatalog category for peptides claimed to enhance autophagy; not a recognized compound class in the literature.C-Peptide AnalogsSynthetic peptides related to the proinsulin connecting peptide, whose native form has been studied as an adjunct in type 1 diabetes; analogs are undocumented.